{"filing":{"accession_number":"0000885725-26-000051","cik":"0000885725","ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"bsx-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/bsx-20260729.htm"},"events":[{"id":21331,"run_id":19235,"accession_number":"0000885725-26-000051","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Boston Scientific issued a press release on July 29, 2026 announcing Q2 2026 financial results, including net sales of $5.442 billion (7.5% reported growth), GAAP net income of $0.61 per share, and adjusted EPS of $0.86 per share. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the earnings release furnished as Exhibit 99.1, which is the standard disclosure mechanism for quarterly earnings announcements.","company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":20951,"accession_number":"0000885725-26-000051","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Boston Scientific issued a press release on July 29, 2026 announcing Q2 2026 financial results, including net sales of $5.442 billion (7.5% reported growth), GAAP net income of $0.61 per share, and adjusted EPS of $0.86 per share. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the earnings release furnished as Exhibit 99.1, which is the standard disclosure mechanism for quarterly earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T10:34:37.615722+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20951,"accession_number":"0000885725-26-000051","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Boston Scientific issued a press release on July 29, 2026 announcing Q2 2026 financial results, including net sales of $5.442 billion (7.5% reported growth), GAAP net income of $0.61 per share, and adjusted EPS of $0.86 per share. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the earnings release furnished as Exhibit 99.1, which is the standard disclosure mechanism for quarterly earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T10:34:37.615722+00:00","company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","filing_date":"2026-07-29"}]}